A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
- Conditions
- Prostate Cancer
- Registration Number
- NCT00036543
- Lead Sponsor
- Abbott
- Brief Summary
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1000
- Diagnosis of prostate cancer.
- Rising PSA while on hormonal therapy or following surgical castration.
- Documented evidence of metastatic disease.
- Have received cytotoxic chemotherapy.
- Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The primary objective of this study is to evaluate safety and efficacy as measured by time-to-disease progression
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (232)
Urology Centers Of Alabama
🇺🇸Homewood,, Alabama, United States
Alaska Clinical Research Center, LLC
🇺🇸Anchorage, Alaska, United States
Advanced Clinical Trials
🇺🇸Tucson, Arizona, United States
Arkansas Urologial Associates, PA
🇺🇸Little Rock, Arkansas, United States
Robin V. Smith, MD
🇺🇸Chula Vista, California, United States
Urology Associate Of Central California
🇺🇸Fresno,, California, United States
South Valley Medical Plaza
🇺🇸Gilroy, California, United States
San Diego Urology Center
🇺🇸La Mesa, California, United States
UCLA School Of Medicine
🇺🇸Los Angeles,, California, United States
UCLA School of Medicine
🇺🇸Los Angeles, California, United States
Scroll for more (222 remaining)Urology Centers Of Alabama🇺🇸Homewood,, Alabama, United States